

Dabur

03 August 2021

RESULT UPDATE

Sector: FMCG	Rating: HOLD
CMP: Rs 614	Target Price: Rs 585

Stock Info

Sensex/Nifty	53,823 / 16,130
Bloomberg	DABUR IN
Equity shares (mn)	1,767
52-wk High/Low	Rs 619/472
Face value	Rs 1
M-Cap	Rs1,085bn/USD 14.7bn
3-m Avg volume	USD 26.8mn


Financial Snapshot (Rs mn)

Y/E Mar	FY21	FY22E	FY23E
Sales	95,617	108,769	121,551
PAT	16,960	18,800	21,848
EPS (Rs)	9.6	10.6	12.4
PE (x)	64.0	57.7	49.7
EV/EBITDA (x)	46.9	40.5	35.1
P/BV (x)	14.2	12.5	11.0
EV/Sales	9.8	8.6	7.6
RoE (%)	23.8	23.0	23.6
RoCE (%)	27.1	28.0	29.1
NWC (days)	15	18	18
Net gearing (x)	(0.1)	(0.2)	(0.3)

Shareholding Pattern (%)

	Jun 21	Mar 21	Dec 20
Promoter	67.4	67.4	67.9
-Pledged	-	-	-
FII	20.6	19.8	18.5
DII	4.7	5.3	5.9
Others	7.4	7.5	7.7

Stock Performance (1-year)



Premal Kamdar
premalkamdar@systematixgroup.in
+91 22 6704 8090

Ashutosh Joytiraditya
ashutoshj@systematixgroup.in
+91 22 6704 8068

Volumes surprise positively; valuation caps upside

Dabur reported an all-round beat in 1QFY22. Domestic revenues grew 35.4% YoY, driven by volume growth of 34.4% vs. consensus and our estimate of 18% YoY growth. Its 2-year CQGR was also impressive at 10.2%. The outperformance was led by a recovery in Foods and Home & Personal care (HPC) segments although on a favourable base and stable healthcare division growth. It continued to gain market share across key categories through its innovation-led strategy and increased distribution. Gross margin contracted 131bps YoY but EBITDA margin expanded 10bps YoY to 21.1% (vs. our estimates of 20.3%).

The management's focus on power brands (9 brands that account for ~70% of total sales), product innovation (~5-6% contribution to sales), growing distribution reach (in rural areas; direct reach of 1.3mn) and reorientation of marketing strategy should continue to yield positive results. The company's decision to expand its foods & beverage portfolio has increased the addressable market opportunity from Rs 18bn to ~Rs 80bn; this along with new product launches (targets contribution of 8-10% to sales) should aid growth. It expects rural (~45% of domestic revenues) growth rates to outperform urban, leading to market share led growth. The international business (~25.6% of total sales) is expected to deliver double-digit growth in FY22. The management expects to maintain, if not improve, EBITDA margins in FY22. However, growth moderation in its healthcare division (~39% of FY21 domestic revenues) - a key growth driver in FY21 (up 31.9% YoY) - due to subsiding COVID tailwinds and increasing competition remains a key concern. We increase our EPS estimates by 0.5-0.6% for FY22-23E and target P/E to 47x from 45x to factor in better growth visibility. Consequently, our target price is revised to Rs 585 from Rs 560; however, the current valuation leaves no margin of safety. We therefore reiterate HOLD and recommend waiting for a better entry point.

1Q surprises positively: Dabur's consolidated revenues grew 31.9% YoY led by domestic volume growth of 34.4.3% YoY (vs. estimate of 18% YoY). On a QoQ basis as well, revenues grew 11.8% despite the impact of the 2nd COVID wave. In the domestic business, Home and Personal care (HPC – 45.1% of 1QFY22 domestic sales) and Foods and Beverages (F&B – 19.2% of 1QFY22 domestic sales) witnessed recovery with sales growth of 26.1% YoY (on a base of -14.1% YoY) and 80.4% YoY (on a base of -34.5% YoY), respectively. The Healthcare division (35.7% of 1QFY22 domestic sales) grew 30% YoY (on a base of 27.7% YoY). Healthcare revenues on a 2-year CQGR basis improved from 3.6% in 4QFY21 to 28.8% in 1QFY22. International business revenues grew 28.2% YoY (on a base of -21.7% YoY). Consolidated gross margin contracted 131bps YoY to 48.1% due to 9-10% inflation in raw material costs. EBITDA margin, however, expanded 10bps YoY to 20.1% led by price increases (3%), cost savings (Rs 200mn for the quarter), reduction in trade margins and promotional offers. Reported PAT grew 28.4% YoY.

Recovery in HPC and Foods division offsets moderation in healthcare revenue: In the healthcare division, revenues from health supplements (~60% of healthcare revenues) moderated to 24.5% YoY on a high base of 52.2% YoY; however, recovery in the HPC and Foods division offset the impact. In the HPC division, oral care/hair oils revenues grew 21.1%/38.4% YoY while Shampoo/Home care revenues grew 41.3%/30.6% YoY. The recovery in this segment was led by market share gains. As per management, Dabur gained a market share of 100bps YoY in oral care to 16.6%

and expects to become a No. 2 player in the category by the end of FY22. In hair oils as well, it gained 160bps YoY market share to 16-17% with a 60bps YoY gain in coconut hair oil. In foods, beverages grew 85% YoY (on a base of 34.5% YoY) while foods grew 17.8% YoY led by the increase in-home consumption. By launching low SKUs (Rs 10 and Rs 20), PET bottles and entering the fruit drinks market, Dabur has expanded its addressable market size from Rs 18bn to Rs 80bn. New products contributed to 8-10% of the foods division revenues and to 5-6% of the company's overall revenues.

Maintains double-digit growth guidance with stable EBITDA margins: The management has maintained its guidance of double-digit growth backed by a recovery in the HPC and F&B divisions, while growth in the healthcare division is likely to be muted due to a high base. It expects international businesses to deliver double-digit growth rates. It has initiated a price hike of 3% and might take calibrated price increases in 2H to mitigate the impact of raw material inflation. The company expects cost savings of Rs 1bn in FY22 (Rs 0.5bn in FY21) through its Samriddhi project. It plans to invest the benefits of cost-savings in ad spends to support power brands and new products while maintaining stable EBITDA margins in FY22 on a YoY basis. It plans to expand its direct coverage to 1.4mn outlets in FY22 from 1.3mn currently and increase the rural village coverage from 69,000 to 80,000 over the next 2 years. The company has also set up a different sales infrastructure for its Modern trade and e-commerce channels (6-7% of domestic sales in FY21).


Valuations rich; maintain HOLD: We increase our EPS estimates by 0.5-0.6% for FY22-23. We estimate revenue CAGR of 12.7% over FY21-23E led by domestic volume/revenue CAGR of 9.6%/13.5% and a 9.7% CAGR in the international business. New products should continue to contribute 5-6% to the topline. EBITDA margin is likely to expand 60bps over FY21-23 to 21.5% in FY23 aided by cost-saving efforts. We estimate adj. PAT CAGR of 13.5% over FY21-23E. We value the company at a P/E of 47x FY23E EPS (vs. 45x earlier) given improved growth visibility. We maintain our **HOLD** rating as the valuation of 49.7x FY23E EPS remains rich.

Exhibit 1: Quarterly performance


YE March (Rs mn)	1QFY22	1QFY21	4QFY21	YoY (%)	QoQ (%)
Net Revenues	26,115	19,800	23,368	31.9	11.8
Cost of materials	11,435	7,993	9,496	43.1	20.4
(% of sales)	43.8	40.4	40.6		
Purchase of stock in trade	2,118	2,023	2,482	4.7	(14.7)
(% of sales)	8.1	10.2	10.6		
Employee cost	2,582	2,238	2,684	15.4	(3.8)
(% of sales)	9.9	11.3	11.5		
A&P	1,884	1,456	1,542	29.3	22.2
(% of sales)	7.2	7.4	6.6		
Others	2,576	1,924	2,740	33.9	(6.0)
(% of sales)	9.9	9.7	11.7		
EBITDA	5,520	4,166	4,425	32.5	24.8
EBITDA margin (%)	21.1	21.0	18.9		
Other income	848	718	850	18.2	(0.2)
PBIT	6,369	4,884	5,275	30.4	20.7
Depreciation	613	567	666	8.1	(7.9)
Finance Cost	75	78	86	(4.2)	(13.1)
PBT	5,681	4,238	4,522	34.0	25.6
Tax	1,263	793	2,213	59.3	(42.9)
ETR (%)	22.2	18.7	48.9		
Deferred tax	33.5	32.1	(1,469.6)		
Minority interest	(5.3)	(4.8)	(5.3)		
PL of JV/associate	(0.7)	0.1	(5.9)		
Adjusted PAT	4,388	3,418	3,778	28.4	16.1
PATAMI margin	16.8	17.3	16.2		
Exceptional item	0	0	0		
Reported PAT	4,388	3,418	3,778	28.4	16.1
No. of shares (mn)	1,767	1,767	1,767		
Adj EPS (Rs)	2.5	1.9	2.1		

Source: Company, Systematix Institutional Research


Exhibit 2: Domestic volume growth of 34.4% YoY ahead of our estimate of 18% YoY




Source: Company, Systematix Institutional Research

Exhibit 3: Foods revenues outperform other two segments


Source: Company, Systematix Institutional Research

Exhibit 4: International business grew 34.2% in CC terms in 1Q

Source: Company, Systematix Institutional Research

Exhibit 5: Revenues up 31.9% YoY and 11.8% QoQ

Source: Company, Systematix Institutional Research


Exhibit 6: EBITDA margins improve to 21.1% despite gross margin pressure

Source: Company, Systematix Institutional Research

Exhibit 7: Domestic business: Category-wise growth

Category growth (YoY)	1QFY20	2QFY20	3QFY20	4QFY20	1QFY21	2QFY21	3QFY21	4QFY21	1QFY22
Hair care	12%	3%	1%	-20%	-23%	-2%	14%	26%	38%
Oral care	11%	4%	9%	-16%	1%	24%	28%	42%	21%
Skin care	12%	1%	0%	-24%	-13%	38%	9%	39%	-5%
Home care	11%	7%	3%	-18%	-31%	-10%	-1%	22%	31%
Health Supplements	20%	14%	12%	-10%	53%	71%	35%	18%	25%
Digestives	18%	10%	16%	-9%	-12%	3%	0%	19%	16%
OTC & Ethicals	14%	4%	4%	-21%	22%	40%	29%	37%	51%
Foods	2%	-5%	-2%	-21%	-34%	-4%	5%	28%	80%

Source: Company, Systematix Institutional Research

Exhibit 8: Currently trading at 54.4x one-yr fwd P/E

Source: Bloomberg, Systematix Institutional Research

Exhibit 9: Change in estimates

	New estimates		Old estimates		Changes to estimate	
	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E
Revenue	108,769	121,551	106,994	119,635	1.7%	1.6%
EBITDA	22,968	26,147	22,518	25,664	2.0%	1.9%
EBITDA margin	21.1	21.5	21.0	21.5	7bps	6bps
PAT	18,800	21,848	18,685	21,747	0.6%	0.5%
EPS	10.6	12.4	10.57	12.30	0.6%	0.5%

Source: Company, Systematix Institutional Research

FINANCIALS (CONSOLIDATED)

Profit & Loss Statement

YE: Mar (Rs mn)	FY19	FY20	FY21	FY22E	FY23E
Net Sales	85,331	87,036	95,617	108,769	121,551
RM Cost	35,061	36,856	38,064	43,725	48,256
Purchase of trad. Goods	8,030	6,746	9,825	11,177	12,490
Gross Profits	42,240	43,434	47,727	53,867	60,805
Employee costs	9,379	9,477	10,335	11,161	12,054
Selling & Admin costs	15,466	16,033	17,366	19,738	22,604
Total Expenses	67,935	69,112	75,590	85,801	95,405
EBITDA	17,396	17,924	20,027	22,968	26,147
Depreciation	1,769	2,205	2,401	2,525	2,640
Other income	2,962	3,053	3,253	3,903	4,684
EBIT	18,588	18,772	20,878	24,346	28,191
cost	596	495	308	244	181
PBT	17,993	18,277	20,570	24,102	28,010
Taxes	2,786	2,797	3,611	5,302	6,162
Adj. PAT	15,206	15,479	16,960	18,800	21,848
Extraordinaries/Exceptional	753	1,000	-	-	-
Reported PAT	14,453	14,479	16,960	18,800	21,848
No. of shares (mn)	1,766	1,767	1,767	1,767	1,767
Adj. EPS	8.6	8.8	9.6	10.6	12.4

Source: Company, Systematix Institutional Research

Cash Flow

YE: Mar (Rs mn)	FY19	FY20	FY21	FY22E	FY23E
PBT	17,993	17,276	20,560	24,102	28,010
Add: Depreciation	1,769	2,205	2,401	2,525	2,640
Add:	(2,366)	(2,001)	(2,300)	(3,659)	(4,504)
Less: taxes paid	(3,507)	(3,089)	(3,213)	(5,302)	(6,162)
Add: other adjustments	1,284	2,325	(186)	-	-
Less: WC changes	(181)	(579)	3,884	(1,167)	(35)
Total OCF	14,991	16,136	21,147	16,499	19,949
OCF w/o WC changes	15,172	16,716	17,263	17,665	19,984
Capital expenditure	(2,344)	(4,175)	(3,112)	(3,000)	(3,000)
Change in investments	5,713	(994)	(10,946)	-	-
/Dividend recd.	-	-	-	-	-
Total ICF	3,369	(5,168)	(14,058)	(3,000)	(3,000)
Free Cash Flows	12,648	11,962	18,035	13,499	16,949
Share issuances	5	1	0	-	-
Change in borrowings	(2,917)	(3,968)	(407)	(1,000)	(1,000)
Dividends	(15,970)	(6,178)	(5,921)	(8,837)	(9,721)
payment	-	-	-	3,659	4,504
Others	-	(285)	194	-	-
Total FCF	(18,882)	(10,430)	(6,134)	(6,178)	(6,217)
Net change in cash	(522)	538	955	7,321	10,732
Opening cash & CE	899	379	917	1,872	9,193
Closing cash & CE	377	917	1,872	9,193	19,925

Source: Company, Systematix Institutional Research

Balance Sheet

YE: Mar (Rs mn)	FY19	FY20	FY21	FY22E	FY23E
Equity capital	1,766	1,767	1,767	1,767	1,767
Reserves and surplus	54,551	64,290	74,868	84,830	96,958
Net worth	56,317	66,058	76,635	86,598	98,725
Minority	313.8	364.6	366.9	366.9	366.9
Total Debt	5,243	4,671	4,833	3,833	2,833
Other LT liabilities	641	676	647	647	647
Total sources	62,514	71,769	82,482	91,444	102,572
Net Block	19,170	22,011	21,924	22,399	22,759
Investment property	521	516	505	505	505
Net deferred tax	(231)	46	40	40	40
Other assets	1,842	6,433	2,494	2,494	2,494
CWIP	638	1,466	1,473	1,473	1,473
Investments	33,588	28,003	41,596	41,596	41,596
Cash	3,282	8,114	13,290	20,611	31,343
Inventories	13,005	13,796	17,343	17,284	19,315
Debtors	8,336	8,139	5,616	7,450	8,325
Other current assets	3,986	4,844	4,050	4,204	4,239
Current Assets	28,608	34,892	40,299	49,549	63,222
Creditors	14,554	14,822	19,153	19,370	21,646
Other CL	7,067	6,775	6,698	7,242	7,873
Current Liabilities	21,621	21,596	25,851	26,612	29,519
Net Working Capital	6,987	13,296	14,449	22,936	33,704
Total Uses	62,514	71,769	82,482	91,444	102,572

Source: Company, Systematix Institutional Research

Ratios

YE: Mar	FY19	FY20	FY21	FY22E	FY23E
Yoy growth in Revenue	10.1	2.0	9.9	13.8	11.8
Yoy growth in EBITDA	7.6	3.0	11.7	14.7	13.8
Yoy growth in Net income	10.9	1.7	9.5	10.9	16.2
Effective tax rate	22.6	25.5	24.6	22.0	22.0
EBITDA margin	20.4	20.6	20.9	21.1	21.5
PAT margin	17.8	17.8	17.7	17.3	18.0
ROACE (pre-tax)	28.9	28.0	27.1	28.0	29.1
ROAE	26.8	25.3	23.8	23.0	23.6
Net debt to equity (x)	0.0	(0.1)	(0.1)	(0.2)	(0.3)
Inventory days	56	58	66	58	58
Debtors days	36	34	21	25	25
Payable days	62	62	73	65	65
NWC days	29	30	15	18	18
Per share numbers (Rs)					
Reported earnings	8.6	8.8	9.6	10.6	12.4
Dividend	2.8	3.0	4.8	5.0	5.5
Free cash	7.2	6.8	10.2	7.6	9.6
Book Value	31.9	37.4	43.4	49.0	55.9
Valuations (x)					
Price to diluted earnings	71.3	70.1	64.0	57.7	49.7
EV / EBITDA	54.6	52.7	46.9	40.5	35.1
Price to sales	11.1	10.9	9.9	8.7	7.8

Source: Company, Systematix Institutional Research

Institutional Equities Team

Nikhil Khandelwal	Managing Director	+91-22-6704 8001	nikhil@systematixgroup.in
Navin Roy Vallabhaneni	President & Head – IE & ECM	+91-22-6704 8065	navin@systematixgroup.in
Equity Research			
Analysts	Industry Sectors	Desk-Phone	E-mail
Rahul Jain	Metals & Mining	+91-22-6704 8066	rahuljain@systematixgroup.in
Ronak Sarda	Auto, Auto Ancillaries	+91-22-6704 8059	ronaksarda@systematixgroup.in
Rakesh Kumar	Banking, Insurance	+91-22-6704 8041	rakeshkumar@systematixgroup.in
Praful Bohra	Pharmaceuticals and Healthcare	+91-22-6704 8064	prafulbohra@systematixgroup.in
Shubhranshu Mishra	NBFCs & Diversified Financials	+91-22-6704 8024	shubhranshumishra@systematixgroup.in
Sanjeev Kumar Singh	Cement, Building Materials, Paints	+91-22-6704 8017	sanjeevsingh@systematixgroup.in
Premal Kamdar	Consumer Staples	+91-22-6704 8090	premalkamdar@systematixgroup.in
Amar Kedia	Infra, Cap Goods, Logistics, Consumer Durables	+91-22-6704 8084	amarkedia@systematixgroup.in
Ashutosh Joytiraditya	Consumer, Retail	+91-22-6704 8068	ashutoshj@systematixgroup.in
Naushad Chaudhary	Chemicals, Textiles, Building Materials, Midcaps	+91-22-6704 8036	naushadchaudhary@systematixgroup.in
Harsh Mittal	Cement, Building Materials, Paints	+91-22-6704 8098	harshmittal@systematixgroup.in
Poorvi Banka	Auto, Auto Ancillaries	+91-22-6704 8063	poorvibanka@systematixgroup.in
Nikhil Shah	Banking, Insurance	+91-22-6704 8091	nikhilshah@systematixgroup.in
Tausif Shaikh	Pharmaceuticals and Healthcare	+91-22-6704 8046	tausifshaikh@systematixgroup.in
Shweta Dikshit	Metals & Mining	+91-22-6704 8042	shwetadikshit@systematixgroup.in
Shilpashree Venkatesh	Macro-Strategy	+91-22-6704 8078	shilpav@systematixgroup.in
Equity Sales & Trading			
Name		Desk-Phone	E-mail
Vipul Sanghvi	Director and Head - Sales	+91-22-6704 8062	vipulsanghvi@systematixgroup.in
Ashok Kumar Agarwal	Sales	+91-22-6704 8058	ashokagarwal@systematixgroup.in
Jigar Kamdar	Sales	+91-22-6704 8060	jigarkamdar@systematixgroup.in
Rahul Khandelwal	Sales	+91-22-6704 8033	rahul@systematixgroup.in
Pawan Sharma	Director and Head - Sales Trading	+91-22-6704 8067	pawansharma@systematixgroup.in
Mukesh Chaturvedi	Vice President and Co Head - Sales Trading	+91-22-6704 8074	mukeshchaturvedi@systematixgroup.in
Vinod Bhuwad	Sales Trading	+91-22-6704 8051	vinodbhuwad@systematixgroup.in
Rashmi Solanki	Sales Trading	+91-22-6704 8097	rashmisolanki@systematixgroup.in
Rahul Thakar	Sales Trading - Derivatives	+91-22-6704 8073	rahulthakar@systematixgroup.in
Vipul Chheda	Dealer	+91-22-6704 8050	vipulchheda@systematixgroup.in
Amit Sawant	Dealer	+91-22-6704 8054	amitsawant@systematixgroup.in
Paras Shah	Dealer	+91-22-6704 8047	parasshah@systematixgroup.in
Suketu Vyas	Dealer	+91-22-6704 8050	suketuvyas@systematixgroup.in
Corporate Access			
Audrey Leolyn Mendonca	Assistant Vice President	+91-22-6704 8088	audreymendonca@systematixgroup.in
Production			
Yukti Vidyarthi	Editor	+91-22-6704 8071	yukti@systematixgroup.in
Mrunali Pagdhare	Production	+91-22-6704 8057	mrunalip@systematixgroup.in
Vijayendra Achrekar	Production	+91-22-6704 8089	vijayendraachrekar@systematixgroup.in
Operations			
Sachin Malusare	Vice President	+91-22-6704 8055	sachinmalusare@systematixgroup.in
Sugandha Rane	Assistant Vice President	+91-22-6704 8056	sugandha@systematixgroup.in
Jignesh Mistry	Manager	+91-22-6704 8049	jigneshmistry@systematixgroup.in
Ravikiran Dasaka	Manager	+91-22-6704 8622	ravikiran@systematixgroup.in
Ravi Agarwal	Assistant Manager	+91-22-6704 8016	raviagarwal@systematixgroup.in

DISCLOSURES/APPENDIX**I. ANALYST CERTIFICATION**

I, **Premal Kamdar, Ashutosh Joytiraditya**; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

II. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:

1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSL through this presentation.

SSSL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.



Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051
 CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 34600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | Investment Advisor SEBI Reg. No. INA000010414 | AMFI : ARN - 64917